Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,517 across all filing types
Latest filing 2024-11-29 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 90% confidence The document is an FF305 Next Day Disclosure Return under the Hong Kong Stock Exchange rules, detailing changes in issued and treasury shares as well as an on-market share repurchase report. It is a regulatory disclosure of the company buying back its own shares, which fits the definition of a Transaction in Own Shares.
2024-11-29 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 95% confidence The document is an FF305 “Next Day Disclosure Return” under Hong Kong Listing Rules, detailing changes in issued shares and treasury shares, including on‐market share repurchases (dates, quantities, prices) and sale of treasury shares. It is a formal report of the company buying back its own shares. This fits the “Transaction in Own Shares” category (Code: POS).
2024-11-28 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return (Form FF305) filed under the Hong Kong Exchange Listing Rules, detailing the issuer’s on‐market share repurchases and treasury share transactions. It provides specific transactional data: dates, number of shares repurchased, repurchase prices, aggregate price paid, and confirmation that repurchases comply with Main Board/GEM Rules. This is clearly a report of transactions in the company’s own shares (share buybacks), matching the “Transaction in Own Shares” category (Code: POS).
2024-11-27 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Stock Exchange listing rules, detailing changes in issued shares and extensive share repurchases (on-market buybacks) and treasury share movements. This is a regulatory disclosure of the company’s own share transactions. It is not a high‐level report (e.g., annual or interim report) nor a simple announcement of a report, but the actual transactional filing. Therefore, it falls under Transaction in Own Shares (Code: POS).
2024-11-26 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF BIOLOGIC LICENSE APPLICATION OF USTEKINUMAB INJECTION
Regulatory Filings Classification · 80% confidence The document is a voluntary announcement on the Hong Kong Exchange website regarding the acceptance of a biologic license application by China’s NMPA. It contains no financial results, management changes, capital movements, or meeting materials. It is a general regulatory announcement that does not fit any more specific category, so it falls under the fallback “Regulatory Filings” (RNS).
2024-11-26 English
NEXT DAY DISCLOSURE RETURNS
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares, treasury shares, share buybacks, and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations that repurchases were made in accordance with exchange rules. There is no financial performance data, earnings information, or management discussion. The document is a regulatory disclosure about share repurchase activity and changes in capital structure, specifically reporting on transactions of the company's own shares. This fits the category of 'Transaction in Own Shares' (POS) which covers share buybacks or sales of own shares. The document length and detail confirm it is the report itself, not just an announcement of a report. Therefore, the correct classification is POS with high confidence.
2024-11-25 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.